Currently, promising therapeutic targets involved in the clinical treatments of IR-related NASH include Glp-1R, Thr-β, sodium-glucose co-transporter 1/2 (Sglt1/2), PPAR, and Fxr. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.